Literature DB >> 22707197

Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation.

Hu Xiaowen1, Sun Yi.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising agent for cancer therapy. However, a number of prostate cancer cells exhibit high resistance to TRAIL effect. In this study, we found that Triptolide, a Chinese medicine, significantly sensitizes prostate cancer cells to TRAIL-mediated cellular apoptosis by up-regulating DR5 expression. Triptolide treatment can suppress Akt/Hdm2 signaling pathway, and lead to p53 accumulation, thereby up-regulating DR5 expression. Taken together, all evidences indicate that Triptolide may become a promising therapeutic agent that prevents the progression of prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22707197     DOI： 10.1007/s11033-012-1737-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN： 0301-4851            Impact factor:   2.316


  33 in total

Review 1.  Dissecting p53-dependent apoptosis.

Authors:  J E Chipuk; D R Green
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

2.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.

Authors:  R Takimoto; W S El-Deiry
Journal:  Oncogene       Date:  2000-03-30       Impact factor: 9.867

3.  MAPKs are not involved in triptolide-induced cell growth inhibition and apoptosis in prostate cancer cell lines with different p53 status.

Authors:  Wei Li; Yong Liu; Xue-Xia Li; Yang Yu; Jing-Jing Wu; Qing Wang; Hong Huo; Li-Ming Wang; Ling Yang
Journal:  Planta Med       Date:  2010-07-06       Impact factor: 3.352

Review 4.  TRAIL and other TRAIL receptor agonists as novel cancer therapeutics.

Authors:  Christina Falschlehner; Tom M Ganten; Ronald Koschny; Uta Schaefer; Henning Walczak
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

5.  p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK.

Authors:  Karen A Boehme; Roman Kulikov; Christine Blattner
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-27       Impact factor: 11.205

6.  The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis.

Authors:  Silvia Colucci; Giacomina Brunetti; Francesco Paolo Cantatore; Angela Oranger; Giorgio Mori; Paolo Pignataro; Roberto Tamma; Felice Roberto Grassi; Alberta Zallone; Maria Grano
Journal:  Apoptosis       Date:  2007-09       Impact factor: 4.677

7.  Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.

Authors:  Bing Z Carter; Duncan H Mak; Wendy D Schober; Martin F Dietrich; Clemencia Pinilla; Lyubomir T Vassilev; John C Reed; Michael Andreeff
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

Review 8.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

9.  Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.

Authors:  Duncan H Mak; Wendy D Schober; Wenjing Chen; Marina Konopleva; Jorge Cortes; Hagop M Kantarjian; Michael Andreeff; Bing Z Carter
Journal:  Mol Cancer Ther       Date:  2009-09-01       Impact factor: 6.261

10.  HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo.

Authors:  L Pukac; P Kanakaraj; R Humphreys; R Alderson; M Bloom; C Sung; T Riccobene; R Johnson; M Fiscella; A Mahoney; J Carrell; E Boyd; X T Yao; L Zhang; L Zhong; A von Kerczek; L Shepard; T Vaughan; B Edwards; C Dobson; T Salcedo; V Albert
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640
View more
  10 in total

1.  Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Authors:  Erik L Brincks; Tamara A Kucaba; Britnie R James; Katherine A Murphy; Kathryn L Schwertfeger; Veena Sangwan; Sulagna Banerjee; Ashok K Saluja; Thomas S Griffith
Journal:  FEBS J       Date:  2015-10-18       Impact factor: 5.542

2.  Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.

Authors:  Sumit Isharwal; Shrey Modi; Nivedita Arora; Charles Uhlrich; Bhuwan Giri; Usman Barlass; Ayman Soubra; Rohit Chugh; Scott M Dehm; Vikas Dudeja; Ashok Saluja; Sulagna Banerjee; Badrinath Konety
Journal:  Prostate       Date:  2017-02-01       Impact factor: 4.104

3.  Traditional Chinese medicines and their active ingredients sensitize cancer cells to TRAIL-induced apoptosis.

Authors:  Bingyu Sun; Yongqiang Liu; Danhua He; Jinke Li; Jiawei Wang; Wulin Wen; Ming Hong
Journal:  J Zhejiang Univ Sci B       Date:  2021-03-15       Impact factor: 3.066

Review 4.  Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.

Authors:  Xiaoyun Dai; Jingwen Zhang; Frank Arfuso; Arunachalam Chinnathambi; M E Zayed; Sulaiman Ali Alharbi; Alan Prem Kumar; Kwang Seok Ahn; Gautam Sethi
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-07

5.  Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II.

Authors:  Keqiang Zhang; Yuelong Ma; Yuming Guo; Ting Sun; Jun Wu; Rajendra P Pangeni; Min Lin; Wendong Li; David Horne; Dan J Raz
Journal:  Mol Ther Oncolytics       Date:  2020-07-06       Impact factor: 7.200

6.  Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway.

Authors:  R Trivedi; R Maurya; D P Mishra
Journal:  Cell Death Dis       Date:  2014-10-16       Impact factor: 8.469

7.  Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells.

Authors:  Yangyang Han; Weiwei Huang; Jiakuan Liu; Dandan Liu; Yangyan Cui; Ruimin Huang; Jun Yan; Ming Lei
Journal:  Theranostics       Date:  2017-04-20       Impact factor: 11.556

Review 8.  Chinese Medicines in the Treatment of Prostate Cancer: From Formulas to Extracts and Compounds.

Authors:  Xueni Wang; Gang Fang; Yuzhou Pang
Journal:  Nutrients       Date:  2018-02-28       Impact factor: 5.717

Review 9.  Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5.

Authors:  Xia Gan; Yonghong Liu; Xueni Wang
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-21

10.  Triptolide induces growth inhibition and apoptosis of human laryngocarcinoma cells by enhancing p53 activities and suppressing E6-mediated p53 degradation.

Authors:  Fei Zhao; Weiwei Huang; Tamgue Ousman; Bin Zhang; Yangyang Han; Daguia Zambe John Clotaire; Chen Wang; Huanhuan Chang; Huanan Luo; Xiaoyong Ren; Ming Lei
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.